Catalent, Inc. Reports Second Quarter Fiscal 2023 Results
February 7, 2023- Q2’23 net revenue of $1.15 billion decreased 6% as reported, or 2% in constant currency(1), compared to Q2’22. Organic, constant-currency net revenue decreased by 4%, compared to Q2’22.
- Q2’23 net earnings of $81 million.
- Q2’23 Adjusted EBITDA(1) of $283 million decreased 9% as reported, or 6% in constant currency, compared to Q2’22.
- Catalent reiterates full-year guidance, including net revenue of $4,625 million to $4,875 million and Adjusted EBITDA of $1,220 million to $1,300 million.
- Moderna and Catalent to extend collaboration to broaden manufacturing partnership across multiple products and formats in North America and Europe.
SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the second quarter of fiscal 2023, which ended December 31, 2022.
Catalent also announced that it will be extending and expanding its manufacturing partnership with Moderna, which will see Catalent support the manufacture of multiple Moderna products in multiple formats across its North American and European biologics drug product facilities. Catalent will continue to provide drug product fill/finish services and production capacity for Moderna’s COVID-19 programs. In addition, there are plans to extend their ongoing partnership to non-COVID-19 programs such as flu and respiratory syncytial virus (RSV) vaccines, beginning with its manufacturing site in Bloomington, Indiana, and to be expanded to its European facility in Anagni, Italy.
“We are well positioned to leverage the diverse investments we have made across our portfolio to support sustainable, long-term, and profitable growth,” commented Alessandro Maselli, President and Chief Executive Officer of Catalent, Inc. “Notably, our extended partnership with Moderna, a pioneer in mRNA technology, and our recently expanded partnership with Sarepta, a leader in gene therapy, build on our long experience with customers in these growth areas. These partnerships underscore the importance we place on our long-term trusted relationships. In addition, we are improving efficiency with the restructuring actions that we have executed recently, and we are bringing a renewed focus on efficiency across our organization as a whole.”
(1) See “Non-GAAP Financial Measures” below and the GAAP to non-GAAP reconciliation provided later in this release.
Second Quarter 2023 Consolidated Results
Net revenue of $1.15 billion decreased 6% reported, or 2% in constant currency, from the $1.22 billion reported for the second quarter a year ago. Overall organic net revenue (i.e., excluding the effect of acquisitions, divestitures, and currency translation) decreased by 4% over the same period.
Net earnings attributable to common shareholders and earnings per basic and diluted share was $81 million, or $0.45 per basic share and $0.44 per diluted share, compared to net earnings attributable to common shareholders of $93 million, or $0.53 per basic and $0.52 per diluted share, in the second quarter a year ago, respectively. A substantial decrease in COVID-19-related revenue quarter-over-quarter was partially offset by a substantial increase in our non-COVID revenue.
EBITDA from operations(1) was $264 million, an increase of $19 million from $245 million in the second quarter a year ago. Second quarter fiscal 2023 Adjusted EBITDA(1) was $283 million, or 25% of net revenue, compared to $310 million, or 25% of net revenue, in the second quarter a year ago. This represents a decrease of 9% as reported and a decrease of 6% on a constant-currency basis, compared to the fiscal 2022 period. The quarter-over-quarter decrease in Adjusted EBITDA was primarily due to a substantial decrease in COVID-19-related revenue.
Adjusted Net Income(1) was $122 million, or $0.67 per diluted share, compared to Adjusted Net Income of $163 million, or $0.90 per diluted share, in the second quarter a year ago.
(1) See “Non-GAAP Financial Measures” below and the GAAP to non-GAAP reconciliation provided later in this release.
Second Quarter 2023 Segment Review
|
(Dollars in millions) |
Three Months Ended |
|
Constant |
|||||||
|
|
2022 |
|
2021 |
|
Change % |
|||||
|
Biologics |
|
|
|
|
|
|||||
|
Net revenue |
$ |
580 |
|
|
$ |
641 |
|
|
(7 |
)% |
|
Segment EBITDA |
|
181 |
|
|
|
199 |
|
|
(7 |
)% |
|
Segment EBITDA margin |
|
31.3 |
% |
|
|
31.1 |
% |
|
|
|
|
Pharma and Consumer Health |
|
|
|
|
|
|||||
|
Net revenue |
|
570 |
|
|
|
577 |
|
|
3 |
% |
|
Segment EBITDA |
|
135 |
|
|
|
147 |
|
|
(3 |
)% |
|
Segment EBITDA margin |
|
23.7 |
% |
|
|
25.4 |
% |
|
|
|
|
Inter-segment revenue elimination |
|
(1 |
) |
|
|
(1 |
) |
|
30 |
% |
|
Unallocated costs |
|
(52 |
) |
|
|
(101 |
) |
|
(44 |
)% |
|
Combined totals |
|
|
|
|
|
|||||
|
Net revenue |
$ |
1,149 |
|
|
$ |
1,217 |
|
|
(2 |
)% |
|
EBITDA from operations |
$ |
264 |
|
|
$ |
245 |
|
|
11 |
% |
|
Biologics segment |
2022 vs. 2021 |
|
2022 vs. 2021 |
||||||||
|
Year-Over-Year Change |
Three Months Ended |
|
Six Months Ended |
||||||||
|
|
Net Revenue |
|
Segment EBITDA |
|
Net Revenue |
|
Segment EBITDA |
||||
|
Organic |
(7 |
)% |
|
(5 |
)% |
|
(5 |
)% |
|
(17 |
)% |
|
Impact of acquisitions |
— |
% |
|
(2 |
)% |
|
— |
% |
|
(2 |
)% |
|
Constant-currency change |
(7 |
)% |
|
(7 |
)% |
|
(5 |
)% |
|
(19 |
)% |
|
Foreign exchange translation impact on reporting |
(3 |
)% |
|
(2 |
)% |
|
(2 |
)% |
|
(1 |
)% |
|
Total % change |
(10 |
)% |
|
(9 |
)% |
|
(7 |
)% |
|
(20 |
)% |
|
Pharma and Consumer Health segment |
2022 vs. 2021 |
|
2022 vs. 2021 |
||||||||
|
Year-Over-Year Change |
Three Months Ended |
|
Six Months Ended |
||||||||
|
|
Net Revenue |
|
Segment EBITDA |
|
Net Revenue |
|
Segment EBITDA |
||||
|
Organic |
— |
% |
|
(7 |
)% |
|
— |
% |
|
(1 |
)% |
|
Impact of acquisitions |
3 |
% |
|
4 |
% |
|
7 |
% |
|
7 |
% |
|
Constant-currency change |
3 |
% |
|
(3 |
)% |
|
7 |
% |
|
6 |
% |
|
Foreign currency translation impact on reporting |
(4 |
)% |
|
(5 |
)% |
|
(6 |
)% |
|
(7 |
)% |
|
Total % change |
(1 |
)% |
|
(8 |
)% |
|
1 |
% |
|
(1 |
)% |
|
Segment Net Revenue as a % of Total Net Revenue |
||||||||||||||
|
|
Three Months Ended |
|||||||||||||
|
|
December 31, |
|
September 30, |
|
June 30, |
|
March 31, |
|
December 31, |
|||||
|
Biologics |
50 |
% |
|
51 |
% |
|
51 |
% |
|
55 |
% |
|
53 |
% |
|
Pharma and Consumer Health |
50 |
% |
|
49 |
% |
|
49 |
% |
|
45 |
% |
|
47 |
% |
|
Net Revenue |
100 |
% |
|
100 |
% |
|
100 |
% |
|
100 |
% |
|
100 |
% |
Balance Sheet and Liquidity
As of December 31, 2022, Catalent had $4.85 billion in total debt, and $4.38 billion in total debt net of cash, cash equivalents, and marketable securities, compared to $3.86 billion in total net debt as of September 30, 2022.
Catalent’s net leverage ratio(1) as of December 31, 2022 was 3.7x, compared to 3.2x at September 30, 2022 and 2.8x as of December 31, 2021.
(1) See “Non-GAAP Financial Measures” below and the GAAP to non-GAAP reconciliation provided later in this release.
Fiscal Year 2023 Outlook
|
|
FY’23 Full Year Guidance |
|
Net revenue |
$4,625 million – $4,875 million |
|
Adjusted EBITDA |
$1,220 million – $1,300 million |
|
Adjusted net income |
$567 million – $648 million |
|
Weighted average shares outstanding – diluted |
181 million – 183 million |
Catalent reiterates its fiscal year 2023 financial outlook issued on November 1, 2022.
Earnings Webcast
The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET today. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast. The webcast replay, along with the supplemental slides, will be available for 90 days in the “Investors” section of Catalent’s website at www.catalent.com.
About Catalent, Inc.
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.
Non-GAAP Financial Measures
Use of EBITDA from operations, Adjusted EBITDA, Adjusted Net Income and Segment EBITDA
Management measures operating performance based on consolidated earnings from operations before interest expense, expense (benefit) for income taxes, and depreciation and amortization, adjusted for the income or loss attributable to non-controlling interests (“EBITDA from operations”). EBITDA from operations is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations.
Catalent believes that the presentation of EBITDA from operations enhances an investor’s understanding of its financial performance. Catalent believes this measure is a useful financial metric to assess its operating performance across periods by excluding certain items that it believes are not representative of its core business and uses this measure for business planning purposes.
In addition, given the significant investments that Catalent has made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of its cost structure. Catalent believes that EBITDA from operations will provide investors with a useful tool for assessing the comparability between periods of Catalent’s ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense. Catalent presents EBITDA from operations in order to provide supplemental information that it considers relevant for the readers of its consolidated financial statements, and such information is not meant to replace or supersede U.S. GAAP measures. Catalent’s definition of EBITDA from operations may not be the same as similarly titled measures used by other companies.
Catalent evaluates the performance of its segments based on segment earnings before non-controlling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax expense (benefit), and depreciation and amortization (“segment EBITDA”). Moreover, under Catalent’s credit agreement, its ability to engage in certain activities, such as incurring certain additional indebtedness, making certain investments and paying certain dividends, is tied to ratios based on Adjusted EBITDA, which is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations. Adjusted EBITDA is the covenant compliance measure used in the credit agreement governing debt incurrence and restricted payments. Because not all companies use identical calculations, Catalent’s presentation of Adjusted EBITDA may not be comparable to similarly titled measures of other companies.
Management also measures operating performance based on Adjusted Net Income and Adjusted Net Income per share. Adjusted Net Income is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP and is subject to important limitations. Catalent believes that the presentation of Adjusted Net Income and Adjusted Net Income per share enhances an investor’s understanding of its financial performance. Catalent believes these measures are a useful financial metric to assess its operating performance across periods by excluding certain items that it believes are not representative of its core business and Catalent uses these measures for business planning purposes. Catalent defines Adjusted Net Income as net earnings adjusted for amortization attributable to purchase accounting and adjustments for other cash and non-cash items included in the table below, partially offset by its estimate of the tax effects of such cash and non-cash items. Catalent believes that Adjusted Net Income and Adjusted Net Income per share provides investors with a useful tool for assessing the comparability between periods of its ability to generate cash from operations available to its stockholders. Catalent’s definition of Adjusted Net Income may not be the same as similarly titled measures used by other companies. Adjusted Net Income per share is computed by dividing Adjusted Net Income by the weighted average diluted shares outstanding.
The most directly comparable U.S. GAAP measure to EBITDA from operations, Adjusted EBITDA, and Adjusted Net Income is net earnings. Included in this release is a reconciliation of net earnings to EBITDA from operations, Adjusted EBITDA and Adjusted Net Income.
Catalent does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable U.S. GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to the variability, complexity and limited visibility of the adjusting items that would be excluded from the non-GAAP financial measures in future periods. When planning, forecasting, and analyzing future periods, Catalent does so primarily on a non-GAAP basis without preparing a U.S. GAAP analysis as that would require estimates for various cash and non-cash reconciling items that would be difficult to predict with reasonable accuracy. For example, equity compensation expense would be difficult to estimate because it depends on Catalent’s future hiring and retention needs, as well as the future fair market value of its common stock, all of which are difficult to predict and subject to constant change. It is equally difficult to anticipate the need for or magnitude of a presently unforeseen one-time restructuring expense or the values of end-of-period foreign currency exchange rates. As a result, Catalent does not believe that a U.S. GAAP reconciliation would provide meaningful supplemental information about its outlook.
Use of Constant Currency
As changes in exchange rates are an important factor in understanding period-to-period comparisons, Catalent believes the presentation of results on a constant-currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Constant-currency information compares results between periods as if exchange rates had remained constant period over period. Catalent uses results on a constant-currency basis as one measure to evaluate its performance. Catalent calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. Catalent generally refers to such amounts calculated on a constant-currency basis as excluding the impact of foreign exchange or being on a constant-currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. Results on a constant-currency basis, as Catalent presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.
Forward-Looking Statements
This release contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “predict,” “hope,” “foresee,” “likely,” “may,” “could,” “target,” “will,” “would,” or other words or phrases with similar meanings. Similarly, statements that describe Catalent’s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the current or future effects of the COVID-19 pandemic or any global health developments on Catalent’s or its customers’ or suppliers’ businesses; participation in a highly competitive market and increased competition that may adversely affect Catalent’s business; demand for its offerings, which depends in part on its customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect Catalent’s results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on Catalent’s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to Catalent’s operations, including risks from rising inflation, disruptions to global supply chains, or from the Ukrainian-Russian war; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar against other currencies; adverse tax legislative or regulatory initiatives or challenges or adjustments to Catalent’s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisition or other transaction that may complement or expand its business or divest of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at existing facilities; offerings and customers’ products that may infringe on the intellectual property rights of third parties; environmental, health, and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to fund Catalent’s existing pension plans; substantial leverage that may limit its ability to raise additional capital to fund operations and react to changes in the economy or in the industry; and exposure to interest-rate risk to the extent of its variable-rate debt preventing it from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in Catalent’s Annual Report on Form 10-K for the fiscal year ended June 30, 2022, filed August 29, 2022. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.
More products. Better treatments. Reliably supplied.™
|
Catalent, Inc. |
||||||||||||||||||
|
Consolidated Statements of Operations |
||||||||||||||||||
|
(Unaudited; dollars and shares in millions, except per share data) |
||||||||||||||||||
|
|
Three Months Ended |
|
FX Impact |
|
Constant Currency |
|||||||||||||
|
|
2022 |
|
2021 |
|
|
|
Change $ |
|
Change % |
|||||||||
|
Net revenue |
$ |
1,149 |
|
|
$ |
1,217 |
|
|
$ |
(42 |
) |
|
$ |
(26 |
) |
|
(2 |
)% |
|
Cost of sales |
|
762 |
|
|
|
812 |
|
|
|
(30 |
) |
|
|
(20 |
) |
|
(2 |
)% |
|
Gross margin |
|
387 |
|
|
|
405 |
|
|
|
(12 |
) |
|
|
(6 |
) |
|
(2 |
)% |
|
Selling, general, and administrative expenses |
|
226 |
|
|
|
228 |
|
|
|
(3 |
) |
|
|
1 |
|
|
1 |
% |
|
Other operating expense, net |
|
23 |
|
|
|
16 |
|
|
|
(2 |
) |
|
|
9 |
|
|
44 |
% |
|
Operating earnings |
|
138 |
|
|
|
161 |
|
|
|
(7 |
) |
|
|
(16 |
) |
|
(10 |
)% |
|
Interest expense, net |
|
47 |
|
|
|
32 |
|
|
|
(1 |
) |
|
|
16 |
|
|
49 |
% |
|
Other (income) expense, net |
|
(23 |
) |
|
|
14 |
|
|
|
(1 |
) |
|
|
(36 |
) |
|
(256 |
)% |
|
Earnings before income taxes |
|
114 |
|
|
|
115 |
|
|
|
(5 |
) |
|
|
4 |
|
|
4 |
% |
|
Income tax expense |
|
33 |
|
|
|
18 |
|
|
|
(2 |
) |
|
|
17 |
|
|
102 |
% |
|
Net earnings |
$ |
81 |
|
|
$ |
97 |
|
|
$ |
(3 |
) |
|
$ |
(13 |
) |
|
(13 |
)% |
|
Less: Net earnings attributable to preferred shareholders |
|
— |
|
|
|
(4 |
) |
|
|
|
|
|
|
|||||
|
Net earnings attributable to common shareholders |
$ |
81 |
|
|
$ |
93 |
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Weighted average shares outstanding – basic |
|
181 |
|
|
|
175 |
|
|
|
|
|
|
|
|||||
|
Weighted average shares outstanding – diluted |
|
181 |
|
|
|
177 |
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Earnings per share: |
|
|
|
|
|
|
|
|
|
|||||||||
|
Basic |
|
|
|
|
|
|
|
|
|
|||||||||
|
Net earnings |
$ |
0.45 |
|
|
$ |
0.53 |
|
|
|
|
|
|
|
|||||
|
Diluted |
|
|
|
|
|
|
|
|
|
|||||||||
|
Net earnings |
$ |
0.44 |
|
|
$ |
0.52 |
|
|
|
|
|
|
|
|||||
|
Catalent, Inc. |
|||||||||||||||||
|
Consolidated Statements of Operations |
|||||||||||||||||
|
(Unaudited; dollars and shares in millions, except per share data) |
|||||||||||||||||
|
|
Six Months Ended |
|
FX impact |
|
Constant Currency |
||||||||||||
|
|
2022 |
|
2021 |
|
|
|
Change $ |
|
Change % |
||||||||
|
Net revenue |
$ |
2,171 |
|
$ |
2,242 |
|
|
$ |
(90 |
) |
|
$ |
19 |
|
|
1 |
% |
|
Cost of sales |
|
1,526 |
|
|
1,513 |
|
|
|
(65 |
) |
|
|
78 |
|
|
5 |
% |
|
Gross margin |
|
645 |
|
|
729 |
|
|
|
(25 |
) |
|
|
(59 |
) |
|
(8 |
)% |
|
Selling, general and administrative expenses |
|
422 |
|
|
411 |
|
|
|
(10 |
) |
|
|
21 |
|
|
5 |
% |
|
Gain on sale of subsidiary |
|
— |
|
|
(1 |
) |
|
|
— |
|
|
|
1 |
|
|
* |
|
|
Other operating expense |
|
25 |
|
|
20 |
|
|
|
(1 |
) |
|
|
6 |
|
|
25 |
% |
|
Operating earnings |
|
198 |
|
|
299 |
|
|
|
(14 |
) |
|
|
(87 |
) |
|
(29 |
)% |
|
Interest expense, net |
|
79 |
|
|
58 |
|
|
|
(1 |
) |
|
|
22 |
|
|
39 |
% |
|
Other expense, net |
|
2 |
|
|
23 |
|
|
|
(9 |
) |
|
|
(12 |
) |
|
(53 |
)% |
|
Earnings before taxes |
|
117 |
|
|
218 |
|
|
|
(4 |
) |
|
|
(97 |
) |
|
(45 |
)% |
|
Income tax expense |
|
36 |
|
|
28 |
|
|
|
(3 |
) |
|
|
11 |
|
|
42 |
% |
|
Net earnings |
$ |
81 |
|
$ |
190 |
|
|
$ |
(1 |
) |
|
$ |
(108 |
) |
|
(57 |
)% |
|
Less: Net earnings attributable to preferred shareholders |
|
— |
|
|
(13 |
) |
|
|
|
|
|
|
|||||
|
Net earnings attributable to common shareholders |
$ |
81 |
|
$ |
177 |
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Weighted average shares outstanding – basic |
|
180 |
|
|
173 |
|
|
|
|
|
|
|
|||||
|
Weighted average shares outstanding – diluted |
|
181 |
|
|
175 |
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Earnings per share: |
|
|
|
|
|
|
|
|
|
||||||||
|
Basic |
|
|
|
|
|
|
|
|
|
||||||||
|
Net earnings |
$ |
0.45 |
|
$ |
1.02 |
|
|
|
|
|
|
|
|||||
|
Diluted |
|
|
|
|
|
|
|
|
|
||||||||
|
Net earnings |
$ |
0.45 |
|
$ |
1.01 |
|
|
|
|
|
|
|
|||||
|
Catalent, Inc. |
|||||
|
Condensed Consolidated Balance Sheets |
|||||
|
(Unaudited; dollars in millions) |
|||||
|
|
December 31, |
|
June 30, |
||
|
ASSETS |
|
|
|
||
|
Current assets: |
|
|
|
||
|
Cash and cash equivalents |
$ |
442 |
|
$ |
449 |
|
Trade receivables, net |
|
916 |
|
|
1,051 |
|
Inventories |
|
818 |
|
|
702 |
|
Prepaid expenses and other |
|
714 |
|
|
625 |
|
Marketable securities |
|
28 |
|
|
89 |
|
Total current assets |
|
2,918 |
|
|
2,916 |
|
Property, plant, and equipment, net |
|
3,579 |
|
|
3,127 |
|
Other non-current assets, including intangible assets |
|
4,650 |
|
|
4,464 |
|
Total assets |
$ |
11,147 |
|
$ |
10,507 |
|
|
|
|
|
||
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|||||
|
Current liabilities: |
|
|
|
||
|
Current portion of long-term obligations and other short-term borrowings |
$ |
632 |
|
$ |
31 |
|
Accounts payable |
|
367 |
|
|
421 |
|
Other accrued liabilities |
|
527 |
|
|
620 |
|
Total current liabilities |
|
1,526 |
|
|
1,072 |
|
Long-term obligations, less current portion |
|
4,221 |
|
|
4,171 |
|
Other non-current liabilities |
|
488 |
|
|
469 |
|
Total shareholders’ equity |
|
4,912 |
|
|
4,795 |
|
Total liabilities and shareholders’ equity |
$ |
11,147 |
|
$ |
10,507 |
Contacts
Investor Contact:
Catalent, Inc.
Paul Surdez
732-537-6325
[email protected]